FREE TREATMENT REPORT

See ratings and reviews when you sign up for an account.

The Evaluation of Women With Perimenopause-Related Mood and Behavioral Disorders

This study is currently Recruiting

June 2011 By National Institutes of Health Clinical Center (CC)

First Recieved on November 3, 1999

Last Updated on June 24, 2011

Sponsor: National Institute of Mental Health (NIMH)
Collaborators:
Information provided by: National Institutes of Health Clinical Center (CC)
Identifier: NCT00001231

Purpose

The purpose of this study is to investigate mood and behavior changes in the time period surrounding and including menopause. This is an observational study; volunteers who participate will not receive any new or experimental therapies. Controversy exists regarding the relationship between estrogen and progesterone (gonadal steroid) changes and midlife-onset depression. This study will examine the role of gonadal steroids in perimenopausal mood and behavioral disorders. Perimenopausal women with depression symptoms and a control group of healthy perimenopausal volunteers will be compared to identify correlates of the occurrence of depression. Participants with depressive symptoms may also participate in companion studies that will test the antidepressant efficacy of phytoestrogens and selective estrogen receptor modulators (SERMS). A group of younger pre-perimenopausal women with normal menstrual cycle functioning will be followed through menopause in an effort to confirm the association of depression onset with changes in reproductive endocrine functioning....

Study Type: Observational
Study Design: N/A

Eligibility

Ages Eligible for Study:40 Years
Genders Eligible for Study:Female
Accepts Healthy Volunteers:Accepts Healthy Volunteers
Criteria

- PATIENT/VOLUNTEER INCLUSION CRITERIA: Cross-sectional Screening: The perimenopausal subjects of this protocol will be women who meet the following inclusion criteria: History within the last one year of at least one month with perimenopause-related mood or behavioral disturbances of at least moderate severity - that is, disturbances that are distinct in appearance and associated with a notable degree of functional impairment; Age 40-60; History of the onset of menstrual irregularity during the past six months but not greater than one year of amenorrhea (i.e., not postmenopausal); Biological evidence of a deterioration of normal ovarian activity, specifically, plasma FSH levels persistently elevated (greater than 14 IU/L) drawn at two week intervals over a period of eight weeks; No prior estrogen replacement therapy for treatment of perimenopausal physical or emotional symptoms within the last six months; and. In good medical health Subjects must be competent to comprehend the purpose of the screening process and to provide written informed consent and be willing to participate in NIMH IRB approved research protocols. CONTROL GROUP INCLUSION CRITERIA: A control group of age-matched perimenopausal women who meet patient selection criteria with the exception of the presence of mood or behavioral disorders will also be sought. CONTROL GROUP EXCLUSION CRITERIA: Subjects should have no general medical illness that is primary (i.e., appears to be causing the mood disorder); Current alcohol or substance use or dependence (excluding nicotine) of sufficient magnitude to require independent, concurrent treatment intervention (e.g., antabuse or opiate treatment, but not including self-help groups) LONGITUDINAL SCREENING INCLUSION CRITERIA: Pre-perimenopausal women will be women who meet the following inclusion criteria: Regular menstrual cycle function (21-34 days); Absence of current mood or behavioral disturbance as determined by a structured diagnostic interview; Plasma gonadotropin levels in pre-perimenopausal range (less than 14 IU/L); In good medical health; and Medication free. GENETIC STUDIES INCLUSION CRITERIA: Unaffected family members of women with perimenopausal depression will be admitted for genetic studies only. First degree relatives of women with confirmed perimenopausal depression, who do not have perimenopausal depression as defined in this protocol.

Investigators

Locations

  • National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland 20892 United States

advertisement
V2012.311.925.327
Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.